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Summary 
T  cells potentially encounter a large number of endogenous self-peptide/MHC ligands  in the 
thymus and the periphery. These endogenous hgands are critical to both positive and negative 
selection in the thymus; however, their effect on peripheral T  cells has not been directly ascer- 
tained. Using the murine allelic Hbd(64-76)/I-E  k self-antigen model, we have previously iden- 
tified altered peptide hgands (APLs) which are able to stimulate some but not all TCR-medi- 
ated effector functions. To determine directly the  effect of endogenously synthesized APL/ 
MHC complexes on peripheral T  cells, we used a TC1L transgenic mouse which had reversed 
our normal antigen system, with Set69 peptide now being the agonist and Hbd(64-76) being 
the APL. In this report, we show that the constitutive level of endogenous Hbd(64-76)/I-E  k 
complexes presented by APCs in vivo is too low to affect the response of Ser69 reactive T cells. 
However, by increasing the number of Hba(64-76)/I-E  k complexes expressed by the APCs, 
TCI:k antagonism is observed for both primary T  cells and T  cell hybridomas. In addition, the 
level of the CD4 coreceptor expressed on T  cells changes the response pattern to endogenously 
presented Hbd(64-76)/I-E  k ligand. These findings demonstrate that T  cells are selected to ig- 
nore the constitutive levels of endogenous complexes they encounter in the periphery. T  cell 
responses can be affected by endogenous APLs in the periphery under limited but attainable 
circumstances which change the efficacy of the TCR/ligand interaction. Thus,  endogenous 
APLs can play a role in both the selection oft  cells in the thymus and the responses of periph- 
eral T  cells. 
A 
series of recent studies has definitively shown that a T 
cell can productively interact through its  TCR  with 
less-than-optimal hgands, resulting in partial T  cell activa- 
tion. These hgands range from peptides with a single amino 
acid substitution to peptides with little amino acid similar- 
ity to the full agonist (1, 2). These peptides bind to MHC 
molecules with the same affinity as the immunogenic pep- 
tide, but are perceived by the TCR in a subtly different way. 
Recognition  of these  altered  peptide  ligands  (APLs) 1 by 
mature T  cells results in the stimulation of some, but not 
all,  TCR-mediated  effector functions  (3).  For  example, 
APLs  can  induce  cytokine production without  prolifera- 
tion (1),  changes in the profile of cytokines produced (4), 
anergy (5), or TCIL antagonism (6-8). We and others have 
viewed the recognition of APLs by T  cells as part of a con- 
tinuum of activation events, encompassed by the term par- 
tial T  cell activation. Therefore, the several different func- 
1Abbreviations used in the paper: APL, altered  peptide ligand; Hb, hemoglo- 
bin; HEL, hen egg-white lysozyme;  PECs, peritoneal exudate cells; Tg, 
transgenic. 
tional assays used to  describe the  effect of APLs,  such as 
anergy induction or TCR antagonism, should be viewed as 
part of the same overall phenomenon. In the thymus, APLs 
could play a major role in both positive and negative selec- 
tion (9-12).  The establishment of the ability of T  cells to 
engage in partial T  cell activation, including anergy induc- 
tion, raised the critical issue  of why peripheral T  cells are 
not all continually anergized, kecent studies have shown 
that APLs do occur naturally, being generated either from 
self-antigens and from pathogens  (2,  13-16), but their ef- 
fect on peripheral T  cells has not been demonstrated. 
In this study, we wanted to investigate the ability of en- 
dogenously  synthesized  self-peptide/MHC  complexes  to 
induce  partial  T  cell  activation  in  peripheral  T  cell  re- 
sponses. To accomplish this, we used our well-estabhshed 
self-antigen model based on the routine [3-minor chain of 
hemoglobin  (Hb).  The  Hb  [3  chain  exists  in  two  allelic 
forms, Hb  ~ and Hb  d, that differ by 12 amino acids,  two of 
which are found in the immunogenic (64-76) peptide se- 
quence. Mice expressing the Hb  S  allele (CE/J and B10.BR, 
H-2  k) generate a strong T  cell response to the Hb  a allelic 
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of T  cell clones and hybridomas, all of which recognize the 
immunodominant Hbd(64-76)/I-E  k determinant. As shown 
by stimulation of these hybridomas with normal APCs from 
CBA/J  (Hb  d,  H-2 k)  mice,  the  minimal  Hbd(64-76)/I-E  k 
epitope is constitutively processed and presented from en- 
dogenous  Hb  d  protein  (17).  We  have  generated  a  TCt/, 
transgenic (G2-Tg) mouse in which the transgenic ~  chain 
derived from a Hbd(64-76)/I-Ek-specific T  cell clone pairs 
with endogenous  ci chains, leading to  a  serendipitous pri- 
mary reactivity to  the  Ser69-peptide, an APL  of Hba(64  - 
76)  (15).  In this system, we have  previously demonstrated 
that synthetic Hbd(64-76)  peptide antagonizes Ser69 reac- 
tive T  ceils in a specific and dose-dependent manner. Thus, 
this transgenic model has reversed our normal antigen sys- 
tem, with Ser69 being the agonist and Hbd(64-76) now be- 
ing an APL. In addition, this transgenic model has allowed 
us to examine the effect of APLs on T  cell activation and in 
vivo T  cell development. In this study, we use antagonism 
of T  cells as our assay for APL-induced partial T  cell activa- 
tion. We determine whether the Ser69 response of purified 
T  cells or T  cell hybridomas derived from the G2-Tg mouse 
can  be  antagonized  by  endogenous  Hbd/I-E  k  complexes. 
Our  findings  reveal  that  endogenous  levels  of Hbd/I-E  k 
complexes are too low to antagonize the T  cells. However, 
when higher levels of complexes are expressed by the APCs, 
TCR  antagonism is observed. We also report that changing 
the  level  of coreceptor  expression directly affects  the  re- 
sponse of the T  cells to  the endogenous ligand. These re- 
sults suggest that peripheral T  cell responses can be affected 
by  endogenous  APLs  under  limited  circumstances  which 
influence the efficacy of the TCR/ligand interaction, such 
as  increased  number  of antagonistic peptide/MHC  com- 
plexes on the APCs or changes in CD4 expression on T  cells. 
Materials and Methods 
Animals.  The generation and characterization of the Hb~/~and 
Hbd/~ G2-TCR transgenic mice have been previously described 
(15).  The  G2-Tg  mice  express  a  functional  V[31-D131-J[32.4 
transgene that is expressed on >95% of the T cells. CBA/J (H-2  k, 
Hb  a) and B10.BR_ (H-2  k, Hb  ~) female mice, 5-10 wk old, were 
purchased from the National Cancer Institute and The Jackson 
Laboratory (Bar Harbor, ME), respectively. 
Antigens.  The Hba(64-76) peptide and the analogue APLs were 
synthesized on either an Applied Biosystems Model 432  (Foster 
City,  CA)  or a  Rainin  Symphony Multiplex synthesizer (Wo- 
burn, MA) and purified by HPLC using a C18 column. The com- 
position, purity,  and  concentration  of the  peptides was  deter- 
mined  by  amino  acid  analysis  using  an  amino  acid  analyzer 
(model 6300;  Beckman Instrs.,  Inc., Fullerton, CA) and by mass 
spectrometry at  the  Washington  University Mass  Spectrometry 
Facility. The amino acid sequences of the peptides using the one 
letter code  are:  Hba(64-76)  =  GKKVITAFNEGLK, Ser69  = 
GKKVISAFNEGLK,  and  MCC(91-103)  =  RADLIAYLKQ- 
ATK. The Hb  ~  and Hb  a proteins were prepared as previously de- 
scribed  (17).  Briefly,  a  hemolysate was  prepared  from  CBA/J 
(Hb  ~t)  or  B10.BP,  (Hb  ~)  blood  by  pelleting the  erythrocytes, 
washing them twice in saline buffer, and then lysing in one vol- 
unle of distilled water. Insoluble nlaterial was  removed by cen- 
trifugation at 10,000 g for 10 min, and the resulting preparation 
contained >95% hemoglobin. The Hb concentration was deter- 
mined by the absorbence at 280 nm. 
Flow Cytometry.  Single cell suspensions were stained in PBS 
supplemented with 0.5% BSA and 0.1% sodium azide. The anti- 
mouse  CD4  mAb  GK1.5  (American Type  Culture  Collection 
[ATCC], R.ockville, MD) was used as primary reagent, followed 
by  a  fluorescein  (FITC)-conjugated  goat  anti-rat  IgG(H+L) 
(Jackson  lmmunoResearch Laboratories, West Grove, PA). Cells 
(10  ~' per sample)  were incubated on ice for 30 rain with the pri- 
mary mAb (neat culture supernatant), washed twice, and labeled 
with FITC-conjugated secondary Ab (1  txg/106 cells) for 30 ram. 
The negative control consisted of cells stained with the secondary 
Ab alone. Cells were washed twice and fixed in I% paraformalde- 
hyde and analyzed on a  FACScan  |  flow cytofluorometer using 
Cell Quest software (Becton-Dickinson, Mountain View, CA). 
T Cell Hybtidomas.  The generation and characterization  of BT9, 
a  Ser69/I-Ek-specific T  cell hybridoma derived from  Hb  ~ (;2- 
TCR_  transgenic  mice  were  previously  described  (15).  BT9- 
CD4 j~  and BT9-CD4 high are subclones of BT9  cells expressing 
low and high cell surface CD4 molecule, respectively. They were 
derived from the BT9 hybrid after staining for CD4 and cell sort- 
ing using a FACS|  (Becton-Dickinson) and a single-cell 
cloning  step.  For  the  generation  of  the  All.F3  hybridoma, 
unprimed spleen cells from Hb  d/~ G2-Tg mice were activated in 
vitro for 4  d  with  Ser69 peptide (50  I.tM),  and fused with  the 
BW5147 TCP,  o~-[3- thymoma (ATCC) according to a standard 
protocol  (18).  The  clonal  hybridomas  were  tested  for  antigen 
specificity using the B  cell line  CH27  as APCs  (19),  and  were 
subcloned for low and high CD4 expression as described above. 
Three additional T  cell hybridomas, YO1.6, specific for Hb'l(64- 
76)/I-E  k  (17),  2B4,  specific  for  cytochrome  c/I-E  k  (20) and 
H6.1,  specific for hen  egg-white lysozyme (HEL)  (84-96)/1-E  k 
(21) have been previously described. T cell hybridomas were cul- 
tured at 37~  in 5% CO2, in RPMI-1640 (GIBCO BRL, Gaith- 
ersburg, MD) medium supplemented with  10% heat-inactivated 
bovine  calf serum  (Hyclone,  Logan,  UT),  2  mM  glutamax 
(GIBCO B1LL), 50  btg/ml gentamicin, and 2  ￿  10 -5 M  2-ME 
(referred to as complete media). 
APC Preparation.  The CH27 B  cell lymphoma (22) and un- 
fractionated,  irradiated  splenocytes  (2,000  rads)  were  used  as 
APCs where indicated. Adherent peritoneal exudate cells (PECs) 
were used as a macrophage-enriched population. PECs were ob- 
tained by peritoneal lavage of mice injected with ConA (60 b~g/ 
ml at day  -7)  and peptone (at day -3)  (23).  PECs  (2  ￿  10s/ 
well) were plated in 96-well microtiter plates in complete media. 
After 2  h  at  37~  the  non-adherent  cells  were  removed,  and 
complete media was added to adherent cells. 
T Cell Hybridoma Activation and TCR Antagonism.  T  cell hy- 
bridomas were stimulated by various amounts ofpeptide and in- 
dicated numbers of APCs following an established protocol (19). 
The stinmlation of the T  cell hybridomas was ascertained by de- 
termining the  level of IL-2  released using the  IL-2-dependent 
cell line, CTLL-2  (ATCC), as described (24).  TCR antagonism 
assays of T  cell hybridomas were  performed as  described  (24). 
Briefly, CH27 were prepulsed with 20 btM of Ser69 peptide for 
2 h at 37~  The cells were washed and plated (5  ￿  104/well)  in 
flat-bottomed 96-well microtiter plates with  5  ￿  104  T  hybri- 
doma cells in the presence of indicated concentrations of Hba(64 - 
76) peptide. After 24 h, T  cell hybridoma stinmlation was deter- 
mined by IL-2 assay as described above. 
Primary T Cell Proliferation.  Proliferation assays of primary T 
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well microtiter plates containing 200 g.1/well ofRPMI-1640 me- 
dium supplemented  with  10% heat-inactivated  FCS  (Hyclone), 
10 m/Vl Hepes (GIBCO BP,  L), 2 mM glutamax,  50 ~g/ml gen- 
tarnicin,  and 2 ￿  10-5 M 2-ME. Purified T cells from Hb  a/~ G2- 
TCR. Tg mice were obtained by passing a single-cell  suspension 
of spleen  cells over a nylon wool column, followed by treatment 
of the  non-adherent  cells with  anti-l-A  k  (10.3.6.2),  anti-I-E  k 
(14.4.4S) (ATCC) and guinea pig and rabbit complement (GIBCO 
BR.L) to remove any remaining class II-positive cells. Purified  T 
cells (5 ￿  10S/well) were cultured in the presence of Ser69 pep- 
tide  (0-100  IzM),  mitomycin c  (Sigma  Chem.  Co.,  St.  Louis, 
MO) treated CH27 cells (5 ￿  104/well),  or irradiated  (2,000 rads) 
CBA/J  or  B10.BR.  spleen  cells (5  ￿  10S/well)  were  used  as 
APCs. Proliferation of the T cells was measured as [3H]TdR. (0.4 
IzCi/well) incorporation over 24 h, as described (25). 
Generation of the CH27mHEL/Hb and CH27mHEL Cell Lines. 
To express  the Hba(64-76)  epitope  on the surface  of an APC, 
CH27 cells were transfected  with a plasmid containing a chimeric 
form of membrane HEL into which the Hba(64-76) epitope was 
inserted.  This  plasmid  was  constructed  from  pCMV2-mHEL, 
which  contains  the  HEL  coding  region  from  a  cDNA  clone 
joined to the 3'  end of the L  a gene  (C.  Nelson, manuscript in 
preparation).  Following the work of Bodmer et al.  (26), the se- 
quence  of the  Hba(64-76)  epitope  was  introduced  between 
amino acids 43-44 of the HEL coding region using PCP,. with 
the following oligonucleotides: GCCTGAAAaaccgtaacaccgatgg- 
gag (coding), and CTTCGTTAAAGGCAGTTATCACCTTTT- 
TGCCtgtagcctgggtgttgaagttac  (non-coding).  These oligonudeotides 
were designed to be directly adjacent to one another, and overlap 
the HEL coding region (lower case) by 20-23 bp. A StuI site was 
introduced at the junction between the oligonucleotides to aid in 
screening recombinants,  and  did  not  alter  the  amino  acid  se- 
quence of the Hba(64-76) epitope. CH27 cells (5 X 106) were co- 
transfected by electroporation  with 65  I~g of pCMV2-mHEL/Hb 
and 3.25 ~g ofa plasmid bearing puromycin resistance,  followed 
by one pulse of  960 IzFarads at 225 V using a Gene pulser (Bio-P, ad, 
Hercules, CA). Cells were seeded into flat-bottom 96-well plates 
and stable  transfectants  were selected  in  1 txg/ml of puromycin 
(Sigma). Drug-resistant colonies were analyzed by direct surface 
staining  using a HTC-conjugated polyclonal rabbit anti-HEL Ab 
(kindly  provided by Emil  Unanue,  Washington  University).  A 
puromycin-resistant clone  that  expressed  high levels  of the  re- 
combinant protein was selected and designated  CH27mHEL/Hb. 
A  control cell  line,  expressing  the  unmodified mHEL protein, 
termed  CH27mHEL,  was  generated  by  transfection  of CH27 
with 50 I~g ofpCMV2-mHEL in a similar manner. This plasmid 
contains  a  hygromycin B-resistance  gene  and  the  transfectants 
were selected  using 450  p.g/ml of hygromycin B  (Calbiochem 
Novabiochem, La Jolla,  CA). 
Statistical Analysis.  The presentation of Ser69 peptide by Hb  a- 
expressing APCs versus Hbs-APCs was compared using Student's 
t test analysis (StatView  II; Abacus, Berkeley, CA). 
Results 
Endogenous HbS /I-E  k Complexes Do Not Antagonize Mature 
T  Cells.  To determine  the effect of endogenous APLs on 
peripheral T  cell responses, we studied TCP, antagonism of 
the  T  cell hybridoma BT9 derived from unprimed lymph 
node cells of G2-Tg mice (15). Unlike the bulk population 
ofT cells derived from G2-Tg mice, BT9 responds only to 
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Ser69,  but not to Hbd(64-76)  peptide  (15).  However,  the 
Ser69 response  of BT9  could be antagonized in a  specific 
and  dose-dependent  manner  by  the  Hba(64-76)  peptide 
when  given  exogenously  to  the  APCs  (15).  Thus,  this 
unique experimental system, in which Ser69 acts as an ago- 
nist and Hba(64-76) as an APL, allowed us to study the ef- 
fect of endogenous Hbd(64-76)/I-E k complexes on the BT9 
response.  To  assay  for  TCt<  antagonism  by  endogenous 
Hbd(64-76)/I-E k complexes,  we  compared  the  Ser69  re- 
sponses of BT9 using normal APCs from Hb  a mice (CBA/ 
J) which express the minimal Hba(64-76)/I-E k epitope, and 
APCs from Hb  ~ mice (B10.BR)  which do not.  If endoge- 
nous  Hbd(64-76)/I-E  k  complexes  could  antagonize  BT9 
cells,  one would expect a depressed response to Ser69 when 
this peptide is presented by APCs from Hb  a mice (CBA/J) 
compared  to  APCs  from  Hb  S mice  (B10.BR.).  The  re- 
sponses of BT9 to Ser69 were identical when  the peptide 
was  presented  by  peritoneal  macrophages  from  CBA/J 
(Hb  a) or B10.BR  (Hbs), which had been activated in vivo 
to induce MHC  class II expression  (Fig.  1 A). Identical re- 
sults  were  obtained  with  splenocytes  (data  not  shown). 
Thus, no antagonism of the BT9 response to Ser69 was ob- 
served  by  endogenous  Hba(64-76)/I-E  k  complexes  ex- 
pressed on B  cells or activated macrophages. The failure of 
endogenously processed Hba(64-76), to antagonize the BT9 
response could be that the level of endogenous complexes 
is too low. Another explanation is that there are differences 
between the endogenous Hba/I-E  k ligand and the synthetic 
peptide  in  either length,  register,  or conformation bound 
to the I-E  k molecule, which could translate into differences 
in antagonist abihty. 
TCR Antagonism  by Hba/I-E  k Complexes  Can Be Detected 
by Increasing the Amount of lib  a Protein Processed and Presented 
by APCs.  To test the hypothesis that the level of endoge- 
nous HbO(64-76)/I-E  k complexes is too low to observe an 
antagonist effect, we added exogenous Hb  a protein  to the 
APCs in vitro. Macrophages were used as APCs because of 
their high endocytic capacity. As shown in Fig.  1 B, signif- 
icant inhibition  of the  Ser69 response was observed when 
macrophages from CBA/J mice were prepulsed with 0.5 to 
1 mg/ml  of Hb  a protein,  as  compared to presentation  by 
Hb~-prepulsed  B10.BR macrophages.  Consistent  with  the 
activity of other TC1L antagonists, the antagonism by Hbd/ 
I-E  k complexes was only observed at low agonist concen- 
trations (0.25 to 0.5 txM). Thus, the failure of the endoge- 
nous Hba(64-76)/I-E k complexes to antagonize the  Ser69 
responses  of BT9  was  apparently  due  to  an  insufficient 
number of complexes expressed on each APC. 
Generation and  Characterization of an APC Line Expressing 
Membrane HEL/Hb Protein.  The antagonistic effect seen by 
addition  of exogenous Hb  d protein was most likely due to 
the processing and presentation of the Hbd(64-76) epitope. 
To  formally demonstrate  this,  we  generated  an APC line 
which presents  high levels  of Hbd(64-76)/I-E  k complexes 
derived  from the  processing  of endogenously synthesized 
protein. 
Hemoglobin is a tetrameric protein composed of two o~ 
and two [3 chains. The free chains are highly unstable  (27), (.9 
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Figure 1.  The abihty of endogenous Hbd/I-E  k complexes to influence T 
cell responses depends on the level of expression. (A) BT9 T cells (5 ￿ 
104/well) were stimulated for 24 h with the indicated concentrations of 
Set69 peptide presented by freshly isolated adherent peritoneal macro- 
phages (PECs) (2 ￿  105/well) from Hb  d (CBA/J) (0) or Hb  ~ (B10.BR) 
(0) mice. (B) The PECs (2 ￿  10S/well) were pulsed for 2 h with a satu- 
rating amount of lib  a (0) or Hb  s (F1) protein (0.5 to 1 mg/ml), washed 
and used to present the indicated concentrations of Set69 peptide to BT9 
cells (5 ￿  104/weU). T cell hybridoma activation was measured by IL-2 
production after 24 h of culture using the CTLL-2 cell line. The values 
represent the mean of triplicate of [3H]TdR incorporation by the CTLL- 
2 cells. In A, the SD were <20% of the mean, and the data are represen- 
tative of five independent experiments, In B, the values represent the 
mean +  SE of five experiments and are statistically different at the 0.5, 
0.25, and 0.125 btM Set69 concentration (P =  0.0242, P <  0.001 and 
P <  0.002, respectively). 
which  hmits  the  usefulness  of expressing  the  Hba(64-76) 
determinant in the form of free [3 chains.  Since membrane 
proteins  expressed  on  the  surface  of APCs  are  efficiently 
processed and presented via the class II processing pathway 
(28,  29), we examined the presentation  of the Hbd(64-76) 
determinant  engineered as part of a membrane protein ex- 
pressed in the APCs. We generated a chimeric membrane 
protein  by  inserting  Hba(64-76)  into  a  transmembrane 
form of the HEL protein, between amino acids 43 and 44, 
as originally described by Bodmer et al.  (26). The presence 
of the Hba(64-76) sequence in HEL in this chimera did not 
appear to have a major effect on the  HEL molecule itself, 
because conformational-dependent Abs still recognized the 
soluble HEL/Hb molecule, and because the chimeric mol- 
ecule  retained  HEL  enzymatic  activity  (C.  Williams,  un- 
pubhshed observation).  CH27 B  lymphoma cells were sta- 
bly  transfected  with  an  expression  plasmid  encoding  the 
hybrid protein,  mHEL/Hba(64-76),  and one line of trans- 
fectants,  CH27mHEL/Hb,  was  chosen  for  its  high  level 
expression of the mHEL/Hb protein. 
The  CH27mHEL/Hb  cells  were  then  tested  for  their 
ability to stimulate both HEL- and Hba(64-76)-specific T  cell 
hybridomas.  The  CH27mHEL/Hb  cells  strongly  stimu- 
lated H6.1,  a hybridoma specific for HEL(84-96)/I-E  k de- 
terminants  (data not shown)  and YO1.6,  a sensitive  T  cell 
hybridoma (ECs0  =  0.001-0.01  p~M) specific for Hba(64 - 
76)/I-E  k complexes  (Fig.  2  A).  These results  indicate  that 
HEL  as  well  as  Hbd(64-76)  determinants  were  efficiently 
processed and presented in association with I-E  k molecules 
by the transfected cells.  The cell surface expression of I-E  k 
by  CH27mHEL/Hb  was  comparable  to  that  of untrans- 
fected CH27  cells  (data not shown).  The level of expres- 
sion ofHba(64-76)/I-E  k complexes by the CH27mHEL/Hb 
cells was  estimated by determining what concentration  of 
exogenous Hba(64-76)  peptide achieved equivalent stimu- 
lation of YO1.6.  As shown in Fig. 2 A, the level of stimu- 
lation  of YO1.6  by CH27mHEL/Hb  was  similar  to  that 
obtained by untransfected CH27 presenting  10 ~M of ex- 
ogenous Hbd(64-76)  peptide.  On  an  individual  cell basis, 
the CH27mHEL/Hb cells were excellent APCs, with as few 
as  30  cells  giving  a  detectable  stimulation  of the  YO1.6 
cells.  Thus, by expressing the Hbd(64-76)  determinant in a 
membrane protein, the APCs efficiently process and present 
the  chimeric  mHEL/Hb  protein  and  stably  present  high 
levels ofHbd(64-76)/I-E  k complexes. 
Estimation  of the  Number  of Endogenous  Hba /I-E  k  Com- 
plexes In Vivo.  To estimate the level of endogenous Hba/ 
I-E  k complexes expressed by normal APCs,  the activation 
of YO1.6 by either normal splenocytes or in vivo-activated 
macrophages from CBA/J mice (Hb  d, H-2  k) was compared 
to activation by CH27mHEL/Hb  (Fig.  2  A).  Indeed,  the 
processing and presentation  of the  Hba(64-76)  epitope  in 
mHEL/Hb protein more closely resembles the situation in 
vivo than adding synthetic Hba(64-76) peptide.  On an in- 
dividual cell basis,  splenocytes and macrophages were ~10- 
and 100-fold less efficient, respectively, than CH27mHEL/ 
Hb in stimulating YO1.6  (Fig. 2 A). The level of stimula- 
tion ofYO1.6 by the splenocytes was equivalent to the ad- 
dition  of 0.001  p~M  Hba(64-76)  peptide  to  CH27  cells. 
These findings are consistent with the idea that no antago- 
nism of the BT9 response was observed with  endogenous 
complexes because they were expressed at insufficient num- 
ber. This hypothesis is supported by the fact that no antag- 
onism was  observed with  0.1  ~xM  of exogenous Hba(64 - 
76) peptide presented by CH27 cells (15). 
High  Levels of Endogenously  Synthesized  Hba/I-E  k  Com- 
plexes Can Antagonize T Cells.  With the CH27mHEL/Hb 
cells expressing much higher levels of Hba(64-76)/I-E  k com- 
plexes than endogenous APCs, one would predict that they 
would be more efficient at antagonizing the BT9 response 
to Ser69. The presentation of Ser69 by CH27mHEL/Hb was 
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Figure 2.  High expression of endogenously synthesized Hbd(64-76)/ 
I-E  k complexes can specifically antagonize T  cells. (A) Graded numbers of 
CH27mHEL/Hb (Q) were tested for their ability to activate YOI.6 (5 ￿ 
104/well),  a  Hba(64-76)/[-Ek-specific  T  cell hybridoma. The activation 
of YO1.6 by CH27mHEL/Hb was compared to that induced by graded 
numbers of either splenocytes (ll~) or PEC (m) derived from CBA/J mice. 
As controls, graded numbers of untransfected CH27 cells cultured in the 
presence of the indicated concentrations of Hbd(64-76) peptide (open sym- 
bols) were added. (B) BT9 cells (10S/well) were activated by the indicated 
amounts of Set69 peptide presented by either untransfected CH27  cells 
([~),  CH27mHEL/Hb  (Q)  or  CH27mHEL  transfected cells  (A)  (5  X 
104/well). T  cell activation was measured as described in Fig. 1. In A, SD 
were ~<20% of the mean and in B, values are the mean +- SD. The results 
are representative of five experiments. 
shifted  10-fold compared to untransfected CH27, indicat- 
ing that endogenous Hba(64-76)/I-E  k complexes presented 
by CH27mHEL/Hb were able to antagonize activation of 
BT9  (Fig.  2  B).  This antagonist effect was specific for the 
Hba(64-76) determinant because CH27 cells transfected with 
mHEL  alone  did  not  affect  the  Ser69  response  of BT9. 
Moreover, both untransfected  and transfected CH27  cells 
which expressed similar levels of I-E  k were equally effective 
in activating the cytochrome c/I-Ek-specific 2B4 T  cell hy- 
bridoma  (data not shown).  CH27mHEL/Hb transfectants 
antagonized the Ser69 response of BT9 as effectively as un- 
transfected  CH27  with  10  ~M  of Hbd(64-76)  synthetic 
peptide  (data not shown). This latter observation confirms 
our estimation of the  number of complexes expressed by 
CH27mHEL/Hb  as  equivalent  to  those  obtained  by  10 
p.M  of exogenous  Hba(64-76)  peptide  presented  by un- 
transfected  CH27.  These  findings  strongly  suggest  that 
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Hbd(64-76)/I-E  k  complexes  that  are  endogenously  pro- 
cessed and presented do not differ functionally from com- 
plexes  generated  by the  addition  of exogenous  synthetic 
peptides in their ability to induce partial T  cell activation. 
Our results also support the idea that the failure of endoge- 
nous  HbO/I-E  k complexes expressed on  normal APCs  to 
act as APLs is due to the number of complexes being below 
a critical threshold. 
CD4  Interaction with  the  Peptide/MHC  Complexes  Can 
Determine  Whether  a Ligand  Is  Perceived as an Agonist  or an 
Antagonist by Mature T  Cells.  Recent  studies  have shown 
that T  cells  can limit their response to self-ligands by de- 
creasing the  expression of coreceptors (30,  31).  To deter- 
mine the role of coreceptor levels in TCR antagonism, we 
sorted BT9 cells into CD4  high and CD4  l~  populations and 
then isolated subclones stably expressing different levels of 
CD4,  but  similar levels  of CD3.  The  BT9-CD4  l~  and 
BT9-CD4  ~gh lines are representative subclones which ex- 
pressed dramatically different levels of CD4 (Fig. 3, top pan- 
els). CD4 expression on the BT9-CD4  l~  cells was similar 
to  that  of unsorted  BT9  cells,  whereas  the  BT9-CD4  high 
cells  expressed significantly higher  levels.  Both BT9  sub- 
clones were stimulated by Ser69  and,  consistent with  the 
different levels of CD4 expression, the BT9-CD4  ~gh T  cells 
were more reactive to Ser69 than the BT9-CD4  l~  T  cells 
(Fig. 3, bottom panels). Interestingly, BT9-CD4  l~  cells were 
stimulated only by Ser69, whereas BT9-CD4hig  h cells were 
stimulated by both Ser69 and Hba(64-76) peptides. The re- 
sponse of tile BT9-CD4  l~  cells was identical to that of un- 
sorted BT9  cells,  with Hba(64-76)  acting as an antagonist 
(data  not  shown,  reference  I5).  In  contrast,  Hba(64-76) 
was  a weak agonist for BT9-CD4  high cells  (Fig.  3,  bottom 
right).  Interestingly,  BT9-CD4hig  h  cells  were  also  weakly 
stimulated by endogenous Hba(64-76)/I-E  k complexes ex- 
pressed  on  Hb  a  splenocytes  from  CBA/J  mice  and  on 
CH27mHEL/Hb cells  (data not shown,  Table  1).  To es- 
tablish that CD4 was directly responsible for the Hba(64-76) 
reactivity gained by the BT9-CD4  high cells, we determined 
the effect of anti-CD4 antibodies (Fig.  4).  The addition of 
anti-CD4 mAb profoundly inhibited the response of BT9- 
CD4  high cells  to Hba(64-76) peptide  (Fig.  4 A). Moreover, 
treatment with anti-CD4 mAb converted Hbd(64-76) from a 
weak agonist to a potent antagonist for BT9-CD4  high cells 
(Fig.  4/3). These results demonstrate that the level of CD4 
surface expression on T  cells  can directly affect whether a 
ligand is perceived as an agonist or an antagonist. 
Primary T  Cells Derived from  Hba/s  G2-Tg Mice Can  Be 
Antagonized  by High Levels of Hbd /I-E  k Complexes.  The  last 
question that we addressed was whether endogenous Hbd/ 
I-E  k complexes would act as APLs for peripheral T  cells that 
were  developed  in  the  presence  of  the  antagonist  Hb  a 
ligand. We have shown that the presence of the Hb  a allele 
in G2-Tg mice resulted in the complete elimination of the 
Hba(64-76)  reactive T  cells and the higher-avidity Ser69- 
reactive T  cells,  while leaving low-avidity Ser69-reactive 
T  cells  (15).  Thus,  we  were  able  to  study  the  Set69  re- 
sponse of naive T  cells,  and we have shown that purified 
T  cells  from Hb  a/~ G2-Tg mice  could be specifically an- BT9-CD4 low 
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Figure  3.  Increased CD4 levels 
convert the  Hba(64-76)  peptide 
from an antagonist to an agonist. 
The top panels show cell surface 
expression of CD4 by two sub- 
clones,  BT9-CD4  I'w  (left) and 
BT9-CD4his h (right) obtained  as 
described in Materials and Meth- 
ods.  T  cells  (10r  were 
incubated  with  flae anti-CD4 
mAb  GK1.5  followed  by  a 
FITC-conjugated  goat  anti-rat 
IgG Ab and analyzed by FACS- 
can (solid lind.  Cell staining with 
the secondary Ab alone is shown 
by the dotted line.  The bottom 
panels  show  the  response  of 
BT9-CD4  I~  (left)  and  BT9- 
Cl)4hi~  (right) (5  X  104/well) to 
indicated  concentrations  of 
Ser69  (D)  or  Hba(64-76)  (O) 
presented  by  CH27  cells  (5  ￿ 
104/well).  T  cell activation  was 
measured  as described  in  Fig.  1. 
Values are means -+ SD. The re- 
sults  are  representative  of four 
experiments. 
tagonized by exogenous Hbd(64-76)  peptide (15). As shown 
in  Fig.  5  A,  the Set69  response  of primary T  cells derived 
from Hbd/~  G2-Tg  mice was  not  antagonized  by  endoge- 
nous  Hba/I-E k  complexes  expressed  on  CBA/J  spleno- 
cytes.  However, these primary T  cells were antagonized by 
high  levels  of  Hba(64-76)/I-E k  complexes  presented  by 
CH27mHEL/Hb  cells (Fig.  5  B).  These  results  are consis- 
tent with the findings using T  cell hybridomas derived from 
Hb  s/S G2-Tg  mice  (Fig.  1).  To  analyze  the  effect of CD4 
expression on the ability of these T  cells to be antagonized, we 
used a  Ser69 reactive T  cell hybridoma,  All.F3,  generated 
from  Hb  a/s  G2-Tg  mice  and  sorted  into  CD4 l~  and 
CD4 high populations.  Neither A11.F3-CD4 l~  T  cells,  nor 
A11.F3-CD4 high T  cells were  reactive  to  Hba(64-76)/I-E k 
complexes  (data  not shown).  However,  only the  Ser69  re- 
sponse orAl 1.F3-CD4 high T  cells was specifically antagonized 
by Hba(64-76)/I-E k complexes presented  on CH27mHEL/ 
Hb (Table  1).  Thus,  low-avidity T  cells from Hb a/~ T  mice 
that  express low level of CD4  do  not productively interact 
with  Hbd(64-76)/I-E k complexes,  whereas  if they  express 
higher levels of CD4,  they  can  perceive  this  ligand  as  an 
APL.  Furthermore,  T  cells from Hb  ~/s Tg-mice that express 
Table  1.  Summary qf the Phenotype of Hba(64-76)I-E k Complexes on Ser69-Reactive  T  Cells 
Effect of lib  d (64-76)/I-E k complexes formed by* 
Endogenous  Addition of lib  a  mHEL/Hb  Hb  a (64-76) 
T  cells*  Hb genotype  in vivo level  protein  protein  peptide 
BT9  s/s  -  APL  APL  APL 
BT9-CD4  l~  s/s  -  APL  APL  APL 
BT9-CD4hig  h  s/s  Weak agonist  ND  Agonist  Agonist 
Primary T  cells  d/s  -  ND  APL  APL 
A 1 I-F3-CD4  l~  d/s  -  ND  -  - 
A 11 -F3-CD4 high  d/s  -  ND  APL  APL 
*The primary  T  cells and the T  cell hybridomas  listed were derived from mice expressing  either the Hb ~/~ or Hb  a/~ allele, and all recognized the 
Ser69 peptide as an agonist. 
*The Hb  a (64-76)/I-E  k complexes were formed either by endogenous processing in vivo, addition of exogenous Hb protein in vitro, expression  of 
Hb  a (64-76)  determinant in a chimeric membrane protein on CH27 cells or addition of exogenous synthetic  peptide to the APCs as described  in 
Materials and Methods. The complexes were either not recognized by the T cell hybridomas  (-) or recognized as an antagonist  (APL) or as an ago- 
nist. The rank order of the phenotype ofHba(64-76)/l-E  k complexes is: -  <  APL <  weak agonist <  agonist. 
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Figure  4.  Effect  of anti-CD4 mAb on the reactivity  of BT9-CD4  high 
cells. (A) BT9-CD4  high cells (5  ￿  104/well) were activated by the indi- 
cated  amounts  of Set69  ([~, ~)  and  Hba(64-76)  (0,  O)  peptides  pre- 
sented by CH27 cells (5 ￿  104/well), in the absence ([-1, O) or presence 
(O, C)) of the anti-CD4 mAb GK1.5.  (B) CH27 cells were prepulsed for 
2 h with 20 ~M ofagonist Ser69 peptide, before addition of the indicated 
amounts  of Hba(64-76)  in the absence  (0)  or presence  (O)  of GK1.5 
mAb.  Activation in  the  absence  of added  antagonist  is  depicted  as  a 
dashed line. T  cell activation  was measured  as described in Fig. 1. In A, 
values represent the mean +- SD and in B, SD were less than  15% of the 
mean. These results are representative  of three experiments. 
low levels of CD4  can be antagonized by Hbd(64-76)/I-E k 
complexes,  and  if these  cells have higher  CD4  expression, 
Hba(64-76)/I-E k  complexes  are  recognized  as  an  agonist. 
The  effect of the  Hba(64-76)/I-E k complexes  observed  T 
cell responses  are summarized  in Table  1.  Taken  together, 
these results indicate that the efficacy of the interaction be- 
tween  a  T  cell and an APC  directly influences the  activity 
of an  APL.  Moreover,  these  data  suggest  that  T  cells  that 
have  developed  in  the  presence  of  the  antagonist  Hb  d 
ligand  are  selected  to  ignore  the  constitutive  levels of en- 
dogenous complexes they encounter in the periphery. 
Discussion 
APLs  derived from both  exogenous  as  well as  endoge- 
nous antigens can productively interact with T  cells resulting 
in partial T  cell activation. To investigate whether endoge- 
nously synthesized APLs are able to affect peripheral T  cell re- 
sponses, we studied the response of purified T  cells and T  cell 
hybridomas  from  a  TCR-Tg  mouse  in which  our normal 
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Figure 5.  Primary T cells derived from Hb  d/~ G2-Tg mice are only an- 
tagonized by high expression of Hbd(64-76)/I-E k complexes.  (A) Nylon 
wool-purified T  cells (2  ￿  10S/well) derived from unprimed Hb  d/S G2- 
Tg nfice were incubated  with the indicated concentrations  of Ser69 pep- 
tide presented by splenocytes (5 ￿  10S/well) from either Hb  d (0) or Hb  S 
([i]) mice. (/3) Primary T cells were activated by the indicated amounts of 
Set69  peptide  presented  by  either  untransfected  CH27  cells  (VT), 
CH27mHEL/Hb  (0)  or CH27mHEL transfected  cells (A)  (5  ￿  104/ 
well). The cultures were incubated for 4 d and proliferation was measured 
by incorporation  of [3H]TdR  (0.4 ~Ci/well) over the last 20 h.  In A, 
each data point represents the mean of triplicate cultures  "4- SD. In B, a 
representative  of six separate experiments  is shown.  Results are expressed 
as Acpm obtained by subtracting the mean background  proliferation from 
the mean proliferation  at each  antigen  concentration.  Background  pro- 
liferation  were:  CH27,  4655  cpm;  CH27mHEL,  7016  cpm;  and 
CH27mHEL/Hb, 1530 cpm. 
antigen  system  has  been  reversed:  the  Ser69  peptide  is  an 
agonist  and  Hbd(64-76)  acts  now  as  an  APL.  This  system 
permitted us to examine the ability of endogenous Hba(64 - 
76)/I-E  k  complexes  to  induce  partial  T  cell activation,  as 
detected  by  their  ability  to  be  TCR  antagonists.  We  ob- 
served no detectable antagonism of either primary T  cells or 
T  cell hybridoma  responses  to  Ser69  by endogenous  Hba/ 
I-E  k complexes expressed on normal APCs; however, TCR 
antagonism  was  observed  after  increasing  the  number  of 
endogenous Hba(64-76)/I-E k complexes by raising the Hb a 
antigen concentration or by expressing the Hba(64-76)  de- 
terminant in a membrane protein on APCs. In addition, by 
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APL could be increased (i.e., an antagonist becomes a weak 
agonist). Thus, we contend that in the periphery endoge- 
nous APLs can affect peripheral T  cells under limited but 
attainable circumstances, such as when the number of APL 
complexes on the APCs increases, and/or when a T cell in- 
creases its sensitivity to the ligand. 
The Hba(64-76) epitope derived from endogenous, nat- 
urally processed Hb protein is efficiently and constitutively 
presented by I-E  k molecules on most APCs in the mouse 
(17).  Hb  is  an  abundant  self-protein,  existing  predomi- 
nantly inside erythrocytes, with a minor component being 
bound to haptoglobin (27). Even with its abundance, how- 
ever, the number ofHbd(64-76)/I-E  k complexes expressed 
on APCs appears not to be saturating, being equivalent to 
0.01-0.001 IxM of exogenously added Hbd(64-76) peptide. 
In a study by Marrack and her colleagues (32), no Hba(64  - 
76)  peptide  was  observed among  the  abundant  peptides 
eluted from I-E  k molecules from C3H mice; however, the 
endogenous Hba(64-76)/I-E  k complexes have been previ- 
ously shown to strongly stimulate Hba(64-76)-reactive T cells 
(17).  Circulating  self-antigens,  such  as  HEL,  C5  of the 
complement system and od-anti-trypsin, have been shown 
to be endogenously processed and presented via the class II 
pathway in  vivo  (25,  33,  34).  The  concentration of the 
self-antigen was directly related to the number of endoge- 
nous  complexes detected  (25,  34).  The number of com- 
plexes generated from HEL even at 30 ng/ml was sufficient 
to stimulate specific T  cells (25), but most likely these com- 
plexes would be difficult to detect by current biochemical 
techniques.  In support of this, it has been shown that the 
majority ofself-peptides bound to class II molecules on the 
surface of an APC  are  derived from membrane proteins, 
with the others being derived from circulating antigens (re- 
viewed  in  reference  35).  Thus,  membrane  proteins  on 
APCs are efficiently processed and presented via the class II 
pathway (28, 29). This was dramatically shown in this study 
when the Hbd(64-76) epitope was  expressed as a chimeric 
mHEL/Hb protein, resulting in a 1,000-fold increase in the 
apparent number of endogenous complexes. Therefore, many 
self-antigens can be processed and presented, and have the 
potential to act as APLs, with the membrane proteins on an 
APC being the most highly represented. 
Several studies have now clearly shown flexibility of the 
TCR. in the recognition of antigen. Unrelated peptides can 
stimulate the same T  cell,  a finding that directly relates to 
the  existence of endogenous APLs.  The phenomenon of 
cross-reactivity has  been  observed for T  cells  specific for 
myelin basic protein (36) and human 0d-anti-trypsin (34), 
but the molecular basis was not established. In addition,  a 
recent study has shown that a TCR can recognize at least 
five different overlapping peptides,  highlighting the flexi- 
bility in the TCR recognition of antigen (37).  Moreover, 
two other studies,  which used the protein sequence data- 
bases,  have identified peptides  from endogenous proteins 
(2) and from pathogens (38), which share a minimal degree 
of sequence homology to  the  natural  immunogenic pep- 
tide,  but  are  able  to  stimulate  the  same  T  cells.  In  the 
Hbd(64-76) system, a peptide containing as few as one amino 
acid in common with Hbd(64-76), could stimulate a specific 
T  cell response.  From a search of the SwissProt database, 
two  endogenous ligands,  an agonist and a partial  agonist, 
were also  readily identified (2).  In addition, Wucherpfen- 
nig and colleagues identified several bacterial and viral pep- 
tides capable of stimulating T  cell clones which were de- 
rived from multiple sclerosis patients and which recognized 
the  MBP(84-102)/HLA-DR2b  determinant  (38).  Impor- 
tantly,  a stimulating peptide from EBV was  shown  to be 
processed naturally in an EBV-transformed 13 cell line and 
was  able to activate the T  cells.  These cross-reactive pep- 
tides did not bear a major degree of sequence homology to 
the  natural  agonist  hgand.  Taken  together,  these  studies 
strongly support the idea that one TCR can interact pro- 
ductively with  multiple  endogenous ligands,  and provide 
evidence that such ligands  exist in vivo. 
Our results  support the idea that the failure of endoge- 
nous Hbd(64-76)/I-E  k complexes to antagonize T  cell re- 
sponses is due to a limiting number of complexes expressed 
by normal APCs in vivo, and the fact that T cells have been 
selected to ignore these endogenous levels. However, the 
lack of reactivity of peripheral T  cells to endogenous APLs 
is not absolute and several different situations can be envi- 
sioned that would result in productive interactions occur- 
ring.  In  our  studies,  we  showed  that  an  increase  in  the 
number of APL/MHC complexes on an APC resulted in 
increased activity of the APL. An increase in the expression 
of endogenous APL/MHC  complexes could easily  occur 
in  vivo,  if the  availability  of the  antigen  increases.  This 
might occur by upregulation of the synthesis of a self-pro- 
tein or increased uptake via endocytosis or receptor-medi- 
ated  events.  For  example,  during  an  inflammatory  re- 
sponse,  the  synthesis  of acute  phase  reactive  proteins  is 
induced, and when cells become activated, the expression 
of some cell surface molecules is upregulated.  In addition, 
the  effective concentration of a  self-protein could be in- 
creased by upregulating MHC  class  II  expression on  the 
APCs. The effect of increasing MHC expression may only 
be related to certain self-antigens, such as membrane pro- 
teins,  because  in  our studies  the  up-regulation  of class II 
expression on macrophages by 1FN-y did not raise the level 
of endogenous complexes enough for them to act as APLs. 
Productive interactions between the TCR and APLs could 
also  occur by changes  in  the  T  cell  activation threshold, 
which  might result from production of cytokines locally, 
and/or by changing the expression level ofcoreceptors (CD4, 
CD8),  adhesion molecules (e.g., LFA-1, ICAM-1),  or co- 
stimulator ligands  (e.g.,  CD28, CTLA-4). 
The coreceptors CD4 and CD8 are intimately involved 
in the T  cell recognition of antigen,  contributing both to 
cell-cell adhesion  and to intracellular signaling  (39).  Our 
results  indicate that the effect of an APL is directly influ- 
enced by the level of expression of CD4 on the responding 
T cells and support two previous studies which showed that 
alterations in CD4 expression could change the fine speci- 
ficity of a  TCR  (40,  41).  Moreover, consistent with  our 
findings, recent studies have shown that decreasing cell sur- 
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class II-restricted T  cells converts an agonist ligand into an 
antagonist (30, 31). Thus the coreceptor's interaction with 
the  peptide/MHC  complexes  can  apparently  determine 
whether a peptide antigen is perceived as an agonist or an 
APL. The mechanism by which increased CD4 levels would 
change the activity of a peptide antigen is not known.  It 
could simply be due to an enhanced or prolonged T  cell/ 
APC interaction and/or could involve an enhanced signal- 
ing by the localization of more p56  lck into the TCR com- 
plex (42,  43). In any case, the increased CD4 levels would 
result in an enhanced efficacy of  the T ceI1/APC interaction. 
Our findings support the view of  Jameson and his col- 
leagues  (30),  that there is a major difference between the 
effect of endogenous APLs  on developing T  cells  in  the 
thymus and on peripheral T  cells. Using fetal thymic organ 
cultures,  they  showed  that  during  positive  selection  the 
CD8 levels of developing thymocytes were lowered to avoid 
reactivity of the mature T  cells with the positive selecting 
ligand. In the thymus, endogenous APLs could play a major 
role in both positive and negative selection (9-12). In con- 
trast,  the present studies clearly show that peripheral T  cells 
do not react with the endogenous levels ofAPLs. A possible 
mechanism by which the peripheral T  cells ignore the en- 
dogenous  APLs  might  first  involve  the  selection  of the 
proper avidity of T  cell/APC interactions by matching the 
TCR affinity and coreceptor expression. Second, it has been 
shown that a lower receptor avidity is required for T  cell 
deletion in  the  thymus  than  for  effector T-cell function 
(44),  supporting the  idea  that  the  activation threshold of 
mature resting T  cells might be higher than that of devel- 
oping  thymocytes  (45).  Taken  together,  these  processes 
would prevent T  cells from reacting with their positively 
selecting ligands  in the periphery. Thus, because the pro- 
cess  of positive selection involves the  recognition of self 
peptides, the immune system has developed mechanisms by 
which mature T  cells  do not normally recognize the  en- 
dogenous  APLs,  including  the  positive  selecting  ligands 
themselves. 
Our data suggest that self-proteins are constitutively pro- 
cessed and presented at levels that do not affect T  cell re- 
sponses, which is likely to be an important feature of the 
maintenance of self-tolerance. On the  other hand,  an in- 
ducible expression of endogenous APLs potentially could 
be involved in regulating an immune response. For exam- 
ple, in a pathological situation, where many inflammatory 
mediators and cytokines enhance antigen presentation, en- 
dogenous APLs may be capable of down regulating specific 
T  cells against agonist ligands.  Moreover, endogenous APLs 
might influence the responses activated against foreign anti- 
gens, e.g., by antagonism, anergy induction or by influenc- 
ing the phenotype of the T  cell population being activated. 
Thus, the repertoire of endogenous self-peptides may influ- 
ence susceptibility to disease,  and also play a significant role 
in  the  shaping  of immune  responses  to  all  foreign chal- 
lenges. 
What are the possible effects of natural APLs on periph- 
eral T  cells? First,  APLs can activate different signals from 
those stimulated by agonist ligands.  This results in  a dra- 
matic change in the functional phenotype of  the T cells. For 
example, in the absence of T  cell proliferation, the engage- 
ment of APLs by a TCR can initiate a biological response 
by inducing production of certain cytokines, such as IL-4, 
by providing B cell help (1), or by lysis of target cells (46). 
A recent study demonstrated that engagement of APLs in- 
duced production of TGF-[3 from the T  cells,  a cytokine 
which was not produced upon stimulation by the agonist 
peptide (4). The biological significance of this as a possible 
way of regulating specific T  cell immune responses is high- 
lighted by the observations that TGF-~ administration to 
mice can ameliorate EAE disease severity, and that suppres- 
sion of EAE is associated with the generation ofT cells that 
secrete TGF-I3 (47,  48).  Second, the presence of endoge- 
nous APLs could give the immune system an added layer of 
control of potentially autoreactive T  cells. For example, ifa 
T  cell expressing a TCR reactive to a self-peptide escapes 
deletion in the thymus and arrives in the periphery where 
the agonist peptide is present, or if the processing of a for- 
eign antigen gives rise to some T  cell epitopes which are 
cross-reactive with self-peptides, one can imagine that the 
risk of autoimmune responses could be blocked in the pe- 
riphery by the presence of endogenous APLs. This idea is 
supported by recent studies  demonstrating that APLs that 
could inhibit specific T  cells in vitro were potent inhibitors 
of EAE  in  vivo,  and  could  even  downregulate  disease 
when coinjected with the agonist peptide (49,  50). How- 
ever, the interaction of peripheral T  cells with APL's might 
also have negative consequences. For example, during the 
processing of a foreign antigen, some T  cell epitopes might 
be cross-reactive with endogenous APLs. The recognition 
of some self-peptides in this way could misdirect T  cell re- 
sponses, thus creating a risk of autoimmune responses.  In 
addition, the endogenous partial agonist could induce dis- 
ease by being a molecular mimic of a TCP,. specific for a 
certain pathogen. Several recent papers, using the examples 
of hepatitis  B  virus  and  human  immunodeficiency virus, 
have  documented  that  APLs  of immunogenic  epitopes 
made  by  mutations  in  pathogen  proteins  can  enhance  a 
chronic viral infection (13,  14,  16).  Thus, partial agonists 
and antagonists can be exploited by pathogens as a method 
of evading or misdirecting the immune system (51,  52). Fi- 
nally, the role of specific antigen in the maintenance of T 
cell memory has remained a controversial issue in the liter- 
ature (reviewed in reference 53). It is possible that memory 
T  cells are maintained in the periphery in the  absence of 
foreign antigen by constant engagement of weak ligands. 
Thus, some cross-reactive ligands,  which have lower affn- 
ity for the TCR than the antigenic peptide, could partially 
stimulate  memory T  cells.  Overall,  these  studies  indicate 
that naturally occurring APLs may play a significant role in 
the biology of T  cells. 
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